What is RSV and Why is it ​a Concern for Seniors?

Respiratory Syncytial Virus (RSV) is a common respiratory ⁢virus that⁢ usually causes mild, cold-like symptoms. ‍However, in older adults, RSV can lead to serious complications like pneumonia and bronchitis, exacerbating existing conditions like COPD and heart failure. According to the CDC,RSV is responsible ⁣for⁣ approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults 65 years and older each year in the United States.

Prior to the vaccine, treatment for RSV was largely supportive, focusing on managing symptoms.​ There was no specific antiviral therapy​ widely ‌available.This⁤ made prevention, through measures like handwashing and avoiding close ‌contact with sick individuals, particularly ‍importent.

The New RSV Vaccines: How They Work

Two RSV vaccines have been approved by the FDA: Arexvy (GSK) and Abrysvo (Pfizer). Both vaccines utilize different technologies to stimulate an immune response. Arexvy is a recombinant subunit vaccine, meaning it contains a specific protein from ⁣the RSV virus. ⁢Abrysvo⁤ uses mRNA technology, similar to some COVID-19 vaccines, to deliver genetic instructions to your cells to produce the viral protein.

Clinical‌ trials have demonstrated ⁤a high degree of efficacy. Such as, the PROTECT trial of Abrysvo showed ⁣approximately ‍82.6% efficacy in ⁤preventing RSV-associated lower respiratory tract disease​ (LRTD) in adults aged 60 years and older. ⁢Arexvy demonstrated around 82.6% efficacy in​ preventing RSV-associated LRTD with medical attendance.

Who Shoudl Get the RSV⁢ Vaccine?

The CDC recommends that adults aged 60 ⁣years and older may receive an RSV vaccine,based on shared clinical ⁤decision-making with their healthcare provider. This means‍ a discussion about individual risk factors, potential⁣ benefits, and any concerns is crucial. Factors to consider include overall health⁢ status, underlying medical conditions, and lifestyle.